Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 13;324(4):C951–C962. doi: 10.1152/ajpcell.00528.2022

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors.

Licensed under Creative Commons Attribution CC-BY 4.0. Published by the American Physiological Society.

PMC Copyright notice

Figure 1. — Effect on renal function compared with 5/6Nx + PBO group. A: concentrations of serum creatinine over the course of the study: Sham + PBO (n = 7), 5/6Nx + 3 mg EMPA (n = 8) and 5/6Nx + 15 mg EMPA (n = 11) were lower than 5/6Nx + PBO (n = 9). B: final ACR: Sham + PBO (n = 8), 5/6Nx + 15 mg EMPA (n = 9) and 5/6Nx + TELM (n = 6) were lower than 5/6Nx + PBO (n = 7). C: Ccr (change from baseline): Sham + PBO (n = 7) and 5/6Nx + 15 mg EMPA (n = 11) were higher than 5/6Nx + PBO (n = 9). Values displayed are means ± SE. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, significantly different from 5/6Nx + PBO. EMPA, empagliflozin; 5/6Nx, 5/6 nephrectomized rat model; PBO, placebo; Sham, sham operation; TELM, telmisartan. ACR, urinary albumin-to-creatinine ratio; Ccr, creatinine clearance.